ARGX - Here's Why argenx Stock Is Soaring Today
Shares of argenx (NASDAQ: ARGX), a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. Investors excited about the future of argenx's lead candidate have pushed the stock 37.9% higher as of 12:38 p.m. EDT on Tuesday.
argenx doesn't have any products to sell at the moment, but results of the Adapt trial suggest efgartigimod could become a new treatment option for generalized myasthenia gravis (gMG) patients. An impressive 67.7% of those treated with efgartigimod achieved improvements on their myasthenia gravis activities of daily living (MG-ADL) scores of at least two points. Just 29.7% of patients given a placebo hit the same mark.
Image source: Getty Images.